Malek Okour1, Geo Derimanov2, Rodger Barnett3, Esther Fernandez4, Santiago Ferrer4, Stephanie Gresham5, Mohammad Hossain1, Francisco-Javier Gamo4, Gavin Koh6, Adrian Pereira7, Katie Rolfe8, Deborah Wong9, Graeme Young7, Harshad Rami6, John Haselden4. 1. Clinical Pharmacology Modeling and Simulation (CPMS), GlaxoSmithKline, King of Prussia, PA, USA. 2. Discovery Medicine, Diseases of the Developing World, GlaxoSmithKline, Collegeville, PA, USA. 3. Drug Product Design and Development (DPDD), GlaxoSmithKline, Ware, Herts, UK. 4. Malaria DPU, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain. 5. Mechanistic Safety and Disposition, GlaxoSmithKline, Ware, UK. 6. Diseases of the Developing World, GlaxoSmithKline, Stockley Park, Uxbridge, UK. 7. Bioanalysis, Immunogenicity and Biomarkers (BIB), GlaxoSmithKline, Ware, UK. 8. Statistics, Programming and Data Strategy (SPDS), GlaxoSmithKline, Stockley Park, Uxbridge, UK. 9. Clinical Pharmacology Science & Study Operations (CPSSO), GlaxoSmithKline, Stevenage, Hertfordshire, UK.
Abstract
AIMS: GSK3191607, a novel inhibitor of the Plasmodium falciparum ATP4 (PfATP4) pathway, is being considered for development in humans. However, a key problem encountered during the preclinical evaluation of the compound was its inconsistent pharmacokinetic (PK) profile across preclinical species (mouse, rat and dog), which prevented reliable prediction of PK parameters in humans and precluded a well-founded assessment of the potential for clinical development of the compound. Therefore, an open-label microdose (100 μg, six subjects) first time in humans study was conducted to assess the human PK of GSK3191607 following intravenous administration of [14C]-GSK3191607. METHODS: A human microdose study was conducted to investigate the clinical PK of GSK3191607 and enable a Go/No Go decision on further progression of the compound. The PK disposition parameters estimated from the microdose study, combined with preclinical in vitro and in vivo pharmacodynamic parameters, were all used to estimate the potential efficacy of various oral dosing regimens in humans. RESULTS: The PK profile, based on the microdose data, demonstrated a half-life (~17 h) similar to other antimalarial compounds currently in clinical development. However, combining the microdose data with the pharmacodynamic data provided results that do not support further clinical development of the compound for a single dose cure. CONCLUSIONS: The information generated by this study provides a basis for predicting the expected oral PK profiles of GSK3191607 in man and supports decisions on the future clinical development of the compound.
AIMS: GSK3191607, a novel inhibitor of the Plasmodium falciparumATP4 (PfATP4) pathway, is being considered for development in humans. However, a key problem encountered during the preclinical evaluation of the compound was its inconsistent pharmacokinetic (PK) profile across preclinical species (mouse, rat and dog), which prevented reliable prediction of PK parameters in humans and precluded a well-founded assessment of the potential for clinical development of the compound. Therefore, an open-label microdose (100 μg, six subjects) first time in humans study was conducted to assess the human PK of GSK3191607 following intravenous administration of [14C]-GSK3191607. METHODS: A human microdose study was conducted to investigate the clinical PK of GSK3191607 and enable a Go/No Go decision on further progression of the compound. The PK disposition parameters estimated from the microdose study, combined with preclinical in vitro and in vivo pharmacodynamic parameters, were all used to estimate the potential efficacy of various oral dosing regimens in humans. RESULTS: The PK profile, based on the microdose data, demonstrated a half-life (~17 h) similar to other antimalarial compounds currently in clinical development. However, combining the microdose data with the pharmacodynamic data provided results that do not support further clinical development of the compound for a single dose cure. CONCLUSIONS: The information generated by this study provides a basis for predicting the expected oral PK profiles of GSK3191607 in man and supports decisions on the future clinical development of the compound.
Authors: Graham Lappin; Wilhelm Kuhnz; Roeline Jochemsen; Johannes Kneer; Ajai Chaudhary; Berend Oosterhuis; Willem Jan Drijfhout; Malcolm Rowland; R Colin Garner Journal: Clin Pharmacol Ther Date: 2006-09 Impact factor: 6.875
Authors: Francisco-Javier Gamo; Laura M Sanz; Jaume Vidal; Cristina de Cozar; Emilio Alvarez; Jose-Luis Lavandera; Dana E Vanderwall; Darren V S Green; Vinod Kumar; Samiul Hasan; James R Brown; Catherine E Peishoff; Lon R Cardon; Jose F Garcia-Bustos Journal: Nature Date: 2010-05-20 Impact factor: 49.962
Authors: David Plouffe; Achim Brinker; Case McNamara; Kerstin Henson; Nobutaka Kato; Kelli Kuhen; Advait Nagle; Francisco Adrián; Jason T Matzen; Paul Anderson; Tae-Gyu Nam; Nathanael S Gray; Arnab Chatterjee; Jeff Janes; S Frank Yan; Richard Trager; Jeremy S Caldwell; Peter G Schultz; Yingyao Zhou; Elizabeth A Winzeler Journal: Proc Natl Acad Sci U S A Date: 2008-06-25 Impact factor: 11.205
Authors: Gregory M Goldgof; Jacob D Durrant; Sabine Ottilie; Edgar Vigil; Kenneth E Allen; Felicia Gunawan; Maxim Kostylev; Kiersten A Henderson; Jennifer Yang; Jake Schenken; Gregory M LaMonte; Micah J Manary; Ayako Murao; Marie Nachon; Rebecca Stanhope; Maximo Prescott; Case W McNamara; Carolyn W Slayman; Rommie E Amaro; Yo Suzuki; Elizabeth A Winzeler Journal: Sci Rep Date: 2016-06-13 Impact factor: 4.379
Authors: Matthew M Ippolito; Kara A Moser; Jean-Bertin Bukasa Kabuya; Clark Cunningham; Jonathan J Juliano Journal: Curr Epidemiol Rep Date: 2021-03-14
Authors: Azrin N Abd-Rahman; Sophie Zaloumis; James S McCarthy; Julie A Simpson; Robert J Commons Journal: Antimicrob Agents Chemother Date: 2021-11-29 Impact factor: 5.191